The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...

Vertex Pharmaceuticals achieved compound earnings per share (EPS) growth of 1.5% per year. We do note that extraordinary items have impacted its earnings history. This EPS growth is lower than the ...

The simplest way to invest in stocks is to buy exchange traded funds. But you can do a lot better than that by ...

The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals, NBC ...

The Food and Drug Administration approved Vertex Pharmaceuticals' non-opioid painkiller ... It's a milestone after a long history of unsuccessful efforts to develop painkillers without the ...

Vertex Pharmaceuticals (VRTX) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

On Thursday, the Food and Drug Administration approved the non-opioid pain relievers from Vertex Pharmaceuticals, a new ...

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

Below, check out the roundup of California Healthline's coverage. For today's national health news, read KFF Health News' Morning Briefing.